Stascheit, Frauke 
; Grittner, Ulrike ; Hoffmann, Sarah ; Mergenthaler, Philipp ; Schroeter, Michael ; Ruck, Tobias ; Pawlitzki, Mark ; Blaes, Franz ; Kaiser, Julia ; Schara, Ulrike ; Della-Marina, Adela ; Thieme, Andrea ; Hagenacker, Tim ; Jacobi, Christian ; Berger, Benjamin ; Urban, Peter P. ; Knop, Karl Christian ; Schalke, Berthold ; Lee, De-Hyung ; Kalischewski, Petra ; Wiendl, Heinz ; Meisel, Andreas
; Grittner, Ulrike ; Hoffmann, Sarah ; Mergenthaler, Philipp ; Schroeter, Michael ; Ruck, Tobias ; Pawlitzki, Mark ; Blaes, Franz ; Kaiser, Julia ; Schara, Ulrike ; Della-Marina, Adela ; Thieme, Andrea ; Hagenacker, Tim ; Jacobi, Christian ; Berger, Benjamin ; Urban, Peter P. ; Knop, Karl Christian ; Schalke, Berthold ; Lee, De-Hyung ; Kalischewski, Petra ; Wiendl, Heinz ; Meisel, Andreas 
Abstract
Background Patients with myasthenia gravis (MG) are potentially prone for a severe COVID-19 course, but there are limited real-world data available on the risk associated with COVID-19 for patients with MG. Here, we investigate whether current immunosuppressive therapy (IST) influences the risk of SARS-CoV-2 infection and COVID-19 severity. Methods Data from the German myasthenia gravis registry ...
Owner only: item control page
Altmetric